Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array

by Kweekel, D M, Antonini, N F, Nortier, J W R, Punt, C J A, Gelderblom, H, Guchelaar, H-J
Published 2009

CYP2D6 Metabolism in Frail Elderly Compared to Non-Frail Elderly: A Pilot Feasibility Study

by Opdam, F. L., Modak, A. S., Mooijaart, S. P., Louwerens, M., de Waal, M. W. M., Gelderblom, H., Guchelaar, H.-J.
Published 2015

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells

by van Oosterwijk, J G, van Ruler, M A J H, Briaire-de Bruijn, I H, Herpers, B, Gelderblom, H, van de Water, B, Bovée, J V M G
Published 2013

Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients

by Baas, J. M., Krens, L. L., ten Tije, A. J., Erdkamp, F., van Wezel, T., Morreau, H., Gelderblom, H., Guchelaar, H. J.
Published 2015

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

by Schneider, T. C., de Wit, D., Links, T. P., van Erp, N. P., van der Hoeven, J. J. M., Gelderblom, H., van Wezel, T., van Eijk, R., Morreau, H., Guchelaar, H. J., Kapiteijn, E.
Published 2015

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects

by Dezentjé, V. O., Opdam, F. L., Gelderblom, H., Hartigh den, J., Van der Straaten, T., Vree, R., Maartense, E., Smorenburg, C. H., Putter, H., Dieudonné, A. S., Neven, P., Van de Velde, C. J. H., Nortier, J. W. R., Guchelaar, H.-J.
Published 2015

Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer

by de Wit, D., Schneider, T. C., Moes, D. J. A. R., Roozen, C. F. M., den Hartigh, J., Gelderblom, H., Guchelaar, H. J., van der Hoeven, J. J., Links, T. P., Kapiteijn, E., van Erp, N. P.
Published 2016

EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment†

by Whelan, J. S., Bielack, S. S., Marina, N., Smeland, S., Jovic, G., Hook, J. M., Krailo, M., Anninga, J., Butterfass-Bahloul, T., Böhling, T., Calaminus, G., Capra, M., Deffenbaugh, C., Dhooge, C., Eriksson, M., Flanagan, A. M., Gelderblom, H., Goorin, A., Gorlick, R., Gosheger, G., Grimer, R. J., Hall, K. S., Helmke, K., Hogendoorn, P. C. W., Jundt, G., Kager, L., Kuehne, T., Lau, C. C., Letson, G. D., Meyer, J., Meyers, P. A., Morris, C., Mottl, H., Nadel, H., Nagarajan, R., Randall, R. L., Schomberg, P., Schwarz, R., Teot, L. A., Sydes, M. R., Bernstein, M., Pickering, James, Joffe, Nicola, Kevric, Matthias, Sorg, Benjamin, Villaluna, Doojduen, Wang, Caroline, Perisoglou, Martha, Trani, Leonardo, Potratz, Jenny, Carrle, Dorothe, Wilhelm, Miriam, Zils, Katja, Teske, Carmen
Published 2015